Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
LEVI has reported its Q3 results on schedule, the stock has bounced 4% on the week to $20.53, and yet the short position that spent all of September rebuilding has barely moved.
The short interest story is the most interesting tension here. Short interest hit 8.76% of free float on October 6, a level reached after a 40% month-on-month build that took shares short from roughly 6.4 million in early September to above 9 million. That build was deliberate and patient: it happened across six weeks, with no single session doing heavy lifting. The question now is whether the post-earnings relief gives shorts a reason to unwind or simply a better entry. So far, there is no sign of covering. Shares short ticked up 1.2% on the week even as the stock recovered. Borrowing conditions explain why that is easy to sustain: availability remains extremely loose at 920%, meaning nearly ten shares are available to borrow for every one already borrowed, and the cost to borrow has actually eased 15% on the week to 0.45%. Shorts are under no pressure from the lending market.
Options positioning has shifted meaningfully since the pre-earnings notes published last week. The put/call ratio has dropped to 1.43, now running more than two standard deviations below its 20-day average of 1.56. That is the most bullish options reading of the past month and a genuine reversal from the defensive posture that had built through September. Bulls in the options market are clearly reacting to the print. But that shift sits in contrast to the short book, which has not followed suit. When the PCR and short interest diverge this sharply, the two sides of the market are telling different stories about what the results mean.
The Street remains cautiously constructive but has been trimming targets ahead of the print. Jefferies lowered its target from $27 to $25 on October 1 while keeping a Buy rating. Citigroup, holding at Neutral, cut from $25 to $22 on September 30. BTIG reiterated Buy at $27. The mean price target is $27.53 against a current price of $20.53, implying roughly 34% upside on consensus, but the recent direction of travel is lower targets rather than higher. JP Morgan is the outlier: it raised its target to $34 in early August and remains at Overweight, though that action is now two months old. The bull case rests on DTC growth, a 17th consecutive quarter of positive comparable sales, and expanding non-denim categories. The bear case points to tariff risk, currency drag, slowing China growth, and a share price that has already lost ground despite those operational wins. The PE multiple of 12.3x and EV/EBITDA of 8.5x are not demanding, but the forward earnings momentum factor scores only in the 10th percentile, suggesting analysts see limited near-term earnings growth.
Ownership is tightly held by the Haas family, which collectively controls the majority of economic interest across multiple family members. There is no activist presence on the 13D register. The only notable insider activity in the recent window was a small tax-withholding transaction by the SVP, Global Controller on October 1, a compensation mechanic rather than a discretionary sale.
The last earnings print, in July, sent the stock down 3.3% on the day and a further 3.2% over the following week. Whether this quarter's initial relief holds through the rest of the week, given a short book that has not yet moved to cover, is the key dynamic to track.
See the live data behind this article on ORTEX.
Open LEVI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
